Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00903916 · ClinicalTrials.gov registry record
Effect of Antipsychotics on Appetite Regulation
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 45
- Enrollment target
NCT00903916: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT00903916 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00903916 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate changes in appetite-regulating hormones, body composition (weight, body fat%), and hunger ratings in persons early in treatment with one of four atypical antipsychotic medications (olanzapine, risperidone, ziprasidone, aripiprazole).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-03 |
What the finished NCT00903916 record still lists
NCT00903916 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00903916 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00903916 about?
NCT00903916 is a clinical study titled "Effect of Antipsychotics on Appetite Regulation". The purpose of this study is to evaluate changes in appetite-regulating hormones, body composition (weight, body fat%), and hunger ratings in persons early in treatment with one of four atypical antipsychotic medications (olanzapine, risperidone, ziprasidone, aripiprazole).
What is the current status of trial NCT00903916?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2007-08. Estimated completion is 2012-03.
Who is sponsoring clinical trial NCT00903916?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia